ArticleThe Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology2026
Percutaneous closure of native and residual ventricular septal defects using a diverse range of occluder devices: a single-centre experience.
Article in The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Transcatheter Closure of a Congenital Gerbode Defect in a Child.JACC. Case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTranscatheter closure of ventricular septal defects (VSDs) presents technical challenges in patients with complex anatomies and residual post-surgical defects. This study aimed to evaluate the feasibility, safety, and early outcomes of percutaneous VSD closure using a range of occlusion devices in a heterogeneous patient population.
methodsThis was a retrospective single-centre observational study of patients who underwent percutaneous VSD closure between 2017 and 2024 at a tertiary congenital cardiac centre.
resultsTwenty patients were included (12 females, 8 males) with a median age of 5.5 years (range 6 months-72.9 years) and median body weight of 18 kg (range 6.4-127 kg). Native VSDs were present in 14 patients and residual post-surgical defects in 6. Defect types included perimembranous (n = 13; including 3 Gerbode defects) and muscular (n = 7). Procedural success was achieved in 95% (19/20). Immediate complete occlusion occurred in 65% (13/20), while 7 patients had small residual shunts that remained haemodynamically insignificant at 1-year follow-up. Complications included one case of transient haemolysis and one case of ventricular ectopy requiring surgical device retrieval. No cases of complete heart block, device embolisation, or significant valve injury were observed during follow-up.
conclusionPercutaneous VSD closure using a range of occlusion devices is feasible and safe across different anatomies and age groups, with high procedural success and low complication rates at one-year follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.